Avastin (bevacizumab) / Roche 
Welcome,         Profile    Billing    Logout  
 623 Diseases   1020 Trials   1020 Trials   31540 News 


12345678910111213...391392»
  • ||||||||||  Journal, Real-world evidence, Real-world:  Real-world drug treatment models of novel targeted drugs in Chinese patients with gynecological cancer from 2017 to 2021: A cross-sectional analysis. (Pubmed Central) -  Jun 4, 2024   
    According to the 5-year change in time, poly adenosine diphosphate ribose polymerase inhibitor (PARPi) rated first in terms of usage, with Olaparib ranking first with the highest concentration of 33.44% and Niraparib ranking second overall with the fastest growth in 2021...The top five drugs by total drug costs were Bevacizumab, Carelizumab, Olaparib, Trastuzumab, and Apatinib...Breast cancer and adenocarcinoma are at the top of the female cancer incidence spectrum, which may explain why HER2i multi-drug combination regimen rates highest among multi-drug combination regimens. Future research may concentrate on how novel anti-tumor targeted drugs can minimize the economic burden and maximize the benefits of patient treatment for patients with gynecological cancer.
  • ||||||||||  Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
    Review, Journal:  Neoadjuvant and adjuvant systemic therapy in HCC: Current status and the future. (Pubmed Central) -  Jun 3, 2024   
    Conversely, the use of immunotherapy is currently discouraged after liver transplantation, given the high risk of graft rejection and death. The increasing complexity of HCC management and increased consideration of (neo)adjuvant strategies highlight the critical role of multidisciplinary care when making these decisions.
  • ||||||||||  Avastin (bevacizumab) / Roche
    Journal:  Enhanced Ocular Delivery of Beva via Ultra-Small Polymeric Micelles for Noninvasive Anti-VEGF Therapy. (Pubmed Central) -  May 31, 2024   
    Current anti-VEGF therapies rely on burdensome intravitreal injections of Bevacizumab (Beva)...Comprehensive biocompatibility verifies safety. Overall, this pioneering protein delivery platform holds promise to shift paradigms from invasive intravitreal injections towards simplified, noninvasive administration of biotherapeutics targeting posterior eye diseases.
  • ||||||||||  Tagrisso (osimertinib) / AstraZeneca
    Journal, PD(L)-1 Biomarker:  ATTLAS, IMpower151 and ORIENT-31: Dusting off IMpower150 for Post-Osimertinib in EGFR-Mutated NSCLC? (Pubmed Central) -  May 31, 2024   
    The retrospective subgroup analysis of IMpower150 indicated that the quad regimen (carboplatin, paclitaxel, bevacizumab, atezolizumab) improved PFS and overall survival (OS) in patients with EGFR-mutant NSCLC who progressed on first-generation EGFR-TKIs...MARIPOSA-2 provided the first randomized trial post-osimertinib in EGFR-mutant NSCLC patients with another quad regimen (platinum, pemetrexed, lazertinib, amivantamab)...Here, we discuss how the results of IMpower151 and ATTLAS may rejuvenate interest in a non-EGFR containing quad regimen as a potential post-osimertinib monotherapy treatment. Randomized trials comparing the results of these studies, including the quad regimen of MARIPOSA-2 versus the quad regimen of IMpower151/Impower150/ATTLAS in post-osimertinib (or other 3G EGFR-TKI) progression, are urgently needed.
  • ||||||||||  Avastin (bevacizumab) / Roche
    Trial termination:  Vitrectomy and Bevacizumab for Diffuse Diabetic Macular Edema (clinicaltrials.gov) -  May 31, 2024   
    P3,  N=20, Terminated, 
    Randomized trials comparing the results of these studies, including the quad regimen of MARIPOSA-2 versus the quad regimen of IMpower151/Impower150/ATTLAS in post-osimertinib (or other 3G EGFR-TKI) progression, are urgently needed. Unknown status --> Terminated; undefined
  • ||||||||||  Eylea (aflibercept intravitreal) / Bayer, Regeneron
    Journal:  Perifoveal retinal thickness changes after intravitreal aflibercept injection for choroidal neovascularization in age-related macular degeneration. (Pubmed Central) -  May 30, 2024   
    As aflibercept consists of parts of the extracellular domain of both the VEGFR1 and VEGFR2 receptors, that are held together by a human IgG1 backbone, this makes the binding of aflibercept to VEGF-A and VEGF-B stronger as compared to the binding of the previously used ranibizumab or bevacizumab (by nearly a factor 100 in the case of the most abundant isoform VEGF-A 165). Besides, aflibercept also binds very well to placental growth factor (PIGF), which is also associated with several ocular diseases.
  • ||||||||||  Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis, Visudyne (verteporfin) / Novartis
    Journal:  Clinical Landscape of Central Serous Chorioretinopathy in Germany - Retina.net CSC Registry Report No 1. (Pubmed Central) -  May 28, 2024   
    Patient age and the proportion of women were higher than expected and bilateral active disease was lower than anticipated, highlighting that neither age nor gender should be overemphasized when diagnosing CSC. Therapeutic interventions are heterogeneous and include verteporfin photodynamic therapy, micropulse laser, and anti-VEGF injections in case of secondary CNV.
  • ||||||||||  Review, Journal, Metastases:  Improving survival in metastatic colorectal cancer through optimized patient selection. (Pubmed Central) -  May 28, 2024   
    Current treatment guidelines state that each therapy can be given before or after the others. Generally, sequencing considerations in the refractory setting include multiple variables such as tumor characteristics, toxicities, factors that are important to the patient, response to prior lines of therapy, and extent of disease.
  • ||||||||||  Avastin (bevacizumab) / Roche
    Review, Journal, BRCA Biomarker, PARP Biomarker, IO biomarker:  Drug-Resistant Epithelial Ovarian Cancer: Current and Future Perspectives. (Pubmed Central) -  May 28, 2024   
    Targeted therapies, such as anti-angiogenics (e.g., bevacizumab) and PARP inhibitors (for BRCA-mutated cancers), offer some success, but therapy resistance, through various mechanisms, poses a significant challenge...Beyond standard treatments, the focus of this study extends to alternate targeted agents, including immunotherapies like checkpoint inhibitors, CAR T cells, and vaccines, as well as inhibitors targeting key oncogenic pathways in EOC. Additionally, this chapter covers disease classification, diagnosis, resistance pathways, standard treatments, and clinical data on various emerging approaches, and advocates for a nuanced and personalized approach tailored to individual subtypes and resistance mechanisms, aiming to enhance therapeutic outcomes across the spectrum of EOC subtypes.
  • ||||||||||  Avastin (bevacizumab) / Roche
    Journal, Machine learning, Metastases:  Machine learning application identifies plasma markers for proteinuria in metastatic colorectal cancer patients treated with Bevacizumab. (Pubmed Central) -  May 27, 2024   
    Additionally, this chapter covers disease classification, diagnosis, resistance pathways, standard treatments, and clinical data on various emerging approaches, and advocates for a nuanced and personalized approach tailored to individual subtypes and resistance mechanisms, aiming to enhance therapeutic outcomes across the spectrum of EOC subtypes. We constructed a machine learning model for predicting grade???2 bevacizumab-induced proteinuria, which may provide proteinuria risk assessment for applying bevacizumab in patients with metastatic colorectal cancer.
  • ||||||||||  Journal:  Resistance to anti-EGFR through the successive and cumulative acquisition of two new oncogenic addictions: BRAF and ALK (Pubmed Central) -  May 26, 2024   
    Subsequent to additional progression and given the ALK rearrangement shown on the re-biopsy, 6th-line treatment with alectinib was proposed...This exceptional case is characterized by resistance to anti-EGFR through the successive and cumulative acquisition of two new oncogene addictions. The authors underline the importance of re-biopsy at each progression, leading (if at all feasible) to yet around round of targeted therapy.
  • ||||||||||  Avastin (bevacizumab) / Roche
    Journal:  An Anti-VEGF-B Antibody Reduces Abnormal Tumor Vasculature and Enhances the Effects of Chemotherapy. (Pubmed Central) -  May 25, 2024   
    We examined the anti-VEGF-B-specific monoclonal antibody 2H10 in preclinical xenograft models of breast and colorectal cancer, in comparison with the anti-VEGF-A antibody bevacizumab...Accordingly, treatment resulted in partial inhibition of tumor growth, and significantly improved the response to chemotherapy. Our studies indicate the importance of VEGF-B in tumor growth, and the potential of specific anti-VEGF-B treatment to inhibit tumor development, alone or in combination with established chemotherapies.
  • ||||||||||  Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
    Review, Journal:  Immunotherapy as a Complement to Surgical Management of Hepatocellular Carcinoma. (Pubmed Central) -  May 25, 2024   
    While agents, such as atezolizumab/bevacizumab, have well-established roles as first-line systemic therapy in intermediate- and advanced-stage HCC, the role of immunotherapy in disease amenable to surgical management continues to evolve. In this review, we will discuss the current evidence and aggregate impact of immunotherapy in the context of HCC amenable to surgical management, including its application in the neoadjuvant and adjuvant settings.
  • ||||||||||  Review, Journal:  Insights in Molecular Therapies for Hepatocellular Carcinoma. (Pubmed Central) -  May 25, 2024   
    Established and recommended targeted treatment options that already exist for patients are considered for systemic treatment: atezolizumab/bevacizumab, durvalumab/tremelimumab, sorafenib, lenvatinib, cabozantinib, regorafenib, and ramucirumab. Combination treatment for systemic treatment and local ablative treatment or transarterial chemoembolization and adjuvant and neoadjuvant treatment strategies are under clinical investigation.
  • ||||||||||  Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
    Journal:  Spontaneous rupture of splenic hilar lymph node metastasis from hepatocellular carcinoma. (Pubmed Central) -  May 25, 2024   
    This report provides novel insights into the feasibility and outcomes of atezolizumab and bevacizumab combination therapy in patients with HCC undergoing hemodialysis, highlighting its potential as a viable treatment option with manageable side effects. Although laparoscopic partial liver resection was performed for intrahepatic recurrence, and atezolizumab plus bevacizumab therapy was administered for peritoneal metastases, the patient was alive 25
  • ||||||||||  Avastin (bevacizumab) / Roche
    Clinical data, Journal, Metastases:  Visceral fat and clinical outcome in patients receiving first-line chemotherapy with bevacizumab for metastatic colorectal cancer. (Pubmed Central) -  May 25, 2024   
    This result supports the idea that targeted supplemental oxygen therapy to keep saturations between 97 and 99% can reduce disease progression in infants with stage 2 ROP and potentially decrease the burden of additional procedures. This study demonstrates that a high visceral fat volume is associated with better outcome in patients receiving first-line bevacizumab-based chemotherapy for metastatic colorectal cancer.
  • ||||||||||  Litx (talaporfin) / Light Sciences Oncology
    Journal:  Photodynamic therapy using talaporfin sodium for non-totally resectable malignant glioma. (Pubmed Central) -  May 24, 2024   
    For patients with PRrOC who have exhausted treatment options, nivolumab and mirvetuximab may be considered as alternatives because of their better safety profiles. PDT for malignant glioma is expected to slightly improve local tumor control for non-totally resectable lesions.
  • ||||||||||  Avastin (bevacizumab) / Roche
    Journal:  The Predictors of Early Treatment Effectiveness of Intravitreal Bevacizumab Application in Patients with Diabetic Macular Edema. (Pubmed Central) -  May 24, 2024   
    Patients with severe NPDR had a significantly higher ApoB/ApoA-I ratio (0.70 (0.57-0.87) vs. 0.61 (0.49-0.72), p = 0.049) and lower vitamin D (52.45 (43.10-70.60) ng/mL vs. 40.05 (25.95-55.30) ng/mL, p = 0.025). Alterations in the NLR, PLR, MLR, and SII seem to provide prognostic information regarding the response to bevacizumab in patients with DME, whilst vitamin D deficiency and the ApoB/ApoA-I ratio could contribute to better staging.
  • ||||||||||  Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
    The impact of etiology on patterns of progression of advanced HCC (Track Hub: Liver Tumours) -  May 23, 2024 - Abstract #EASLILC2024EASL_ILC_2915;    
    Background and Aims: Atezolizumab/bevacizumab (A+B) is the recommended first-line treatment for HCC, irrespective of the etiology of the underlying liver disease. Patients with MASLD-HCC were more likely to develop an intrahepatic progression than non-MASLD patients, confirming preclinical data and suggesting biologic differences between tumors arising from different etiologies with potential implications in terms of clinical management.
  • ||||||||||  Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
    Journal:  Risk of Endophthalmitis Based on Cumulative Number of Anti-Vascular Endothelial Growth Factor Intravitreal Injections. (Pubmed Central) -  May 22, 2024   
    Patients with MASLD-HCC were more likely to develop an intrahepatic progression than non-MASLD patients, confirming preclinical data and suggesting biologic differences between tumors arising from different etiologies with potential implications in terms of clinical management. The cumulative endophthalmitis risk per injection and per eye increased with greater number of injections received but appeared to do so at a higher rate during earlier injections and at a lower rate further into the treatment course.